2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156543
    RXFP1 receptor agonist-8 2941271-76-5 98%
    RXFP1 receptor agonist-8 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-8 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 1.8 nM.
    RXFP1 receptor agonist-8
  • HY-156550
    ROCK-IN-8 1621103-79-4 98%
    ROCK-IN-8 (Example 4) is a ROCK inhibitor, with an IC50 value less than 100 nM. ROCK-IN-8 has anti-inflammatory activity. ROCK-IN-8 can be used for research of respiratory and gastro-intestinal diseases.
    ROCK-IN-8
  • HY-156553
    BTK-IN-27 1841502-36-0 98%
    BTK-IN-27 (example 8) is a BTK inhibitor (IC50: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC50: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases.
    BTK-IN-27
  • HY-156556
    c-Fms-IN-14 1898210-99-5 98%
    c-Fms-IN-14 (Example 76) is a c-Fms inhibitor with an IC50 value of 4 nM. c-Fms-IN-14 can be used for research of cancer and autoimmune diseases.
    c-Fms-IN-14
  • HY-156565
    S1P1 agonist 6 2433782-42-2 98%
    S1P1 agonist 6 (Compound I) is a S1P1 agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research.
    S1P1 agonist 6
  • HY-15656B
    Ceritinib mesylate 2055376-74-2 98%
    Ceritinib (LDK378) mesylate is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib mesylate also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib mesylate shows great antitumor potency.
    Ceritinib mesylate
  • HY-156570
    DGKα-IN-3 2648418-86-2 98%
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-156592
    ROCK2-IN-6 2260506-59-8 98%
    ROCK2-IN-6 (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research.
    ROCK2-IN-6
  • HY-156717
    RE-33 2923520-98-1 98%
    RE-33 is an analgesic compound. RE-33 has blood brain barrier penetration ability.
    RE-33
  • HY-156859
    NSC309401 dihydrochloride 77681-42-6 98%
    NSC309401 is an inhibitor of E. coli DHFR (IC50: 189 nM, KD: 14.57 nM).
    NSC309401 dihydrochloride
  • HY-156908
    3-OH-Kynurenamine 99362-47-7 98%
    3-OH-Kynurenamine dihydroiodide is an activator for aryl hydrocarbon receptor (AhR), and thus regulates the immune response. 3-OH-Kynurenamine dihydroiodide upregulates the expressions of Ido1 and Tgfb1, ameliorates the skin inflammation in psoriasis mouse model and kidney damage in nephrotoxic lupus mouse model.
    3-OH-Kynurenamine
  • HY-156915
    Pim-1 kinase inhibitor 13 79492-49-2 98%
    Pim-1 Kinase Inhibitor 13 (compound 10) is a Pim-1 kinase inhibitor with an IC50 of 4.41 μM. Pim-1 Kinase Inhibitor 13 can be utilized in immunology or cancer research.
    Pim-1 kinase inhibitor 13
  • HY-156920
    VDX-111 158983-23-4 98%
    VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model.
    VDX-111
  • HY-156958
    S-72 2446799-14-8 98%
    S-72 inhibits tubulin polymerization and further triggers mitosis-phase cell cycle arrest and cell apoptosis, in addition to suppressing STAT3 signaling.
    S-72
  • HY-156959
    Ovalicin 19683-98-8 98%
    Ovalicin is a multi-target inhibitor that targets MetAP2, HRH2, JAK2 and TRPV1, with anti-inflammatory and anti-atopic dermatitis activities. Ovalicin covalently binds to MetAP2 to inhibit its function, thereby blocking the replication of Enterocytozoon bieneusi and Vittaforma corneae. Ovalicin alleviates intestinal injury and prolongs survival in infected mouse models, without showing obvious hepatorenal toxicity. Ovalicin attenuates LPS-induced calcium influx, reduces the infiltration of macrophages and mast cells in the skin, and regulates the expression of inflammation-related genes such as IL-31, effectively relieving allergic symptoms in mouse models. Ovalicin can be used for the research of microsporidiosis and atopic dermatitis.
    Ovalicin
  • HY-156960
    JNJ-40929837 1191044-42-4 98%
    JNJ-40929837 is a selective and orally active LTA4H (leukotriene A4 hydrolase) inhibitor. JNJ-40929837 effectively inhibits aminopeptidase activity and causes serum accumulation of Pro-Gly-Pro. JNJ-40929837 can be used in asthma research.
    JNJ-40929837
  • HY-156973
    Tiopropamine 39516-21-7 98%
    Tiopropamine is an anti-inflammatory agent, with potential effect on histamine receptor.
    Tiopropamine
  • HY-15698B
    CRT0066101 trihydrochloride 1781742-22-0 98%
    CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects.
    CRT0066101 trihydrochloride
  • HY-156996
    AGI-134 1821461-84-0 98%
    AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis.
    AGI-134
  • HY-157011
    JAK-IN-33 3032404-49-9 98%
    JAK-IN-33 (compound 3 (R)) is a JAK inhibitor.
    JAK-IN-33
Cat. No. Product Name / Synonyms Application Reactivity